AGM
Alpine Global Management’s Xeris Biopharma Holdings XERS Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $701K | Buy |
150,000
+50,000
| +50% | +$234K | 0.16% | 70 |
|
|
2025
Q1 | $549K | Sell |
100,000
-220,000
| -69% | -$1.21M | 0.15% | 84 |
|
|
2024
Q4 | $1.08M | Buy |
320,000
+160,000
| +100% | +$542K | 0.14% | 98 |
|
|
2024
Q3 | $456K | Sell |
160,000
-140,000
| -47% | -$399K | 0.11% | 110 |
|
|
2024
Q2 | $675K | Hold |
300,000
| – | – | 0.12% | 146 |
|
|
2024
Q1 | $663K | Buy |
300,000
+30,000
| +11% | +$66.3K | 0.13% | 112 |
|
|
2023
Q4 | $635K | Sell |
270,000
-30,000
| -10% | -$70.5K | 0.17% | 91 |
|
|
2023
Q3 | $558K | Buy |
300,000
+75,000
| +33% | +$140K | 0.13% | 76 |
|
|
2023
Q2 | $590K | Sell |
225,000
-175,000
| -44% | -$459K | 0.16% | 84 |
|
|
2023
Q1 | $652K | Hold |
400,000
| – | – | 0.25% | 43 |
|
|
2022
Q4 | $532K | Hold |
400,000
| – | – | 0.18% | 49 |
|
|
2022
Q3 | $624K | Buy |
400,000
+50,000
| +14% | +$78K | 0.15% | 60 |
|
|
2022
Q2 | $539K | Buy |
350,000
+33,480
| +11% | +$51.6K | 0.14% | 75 |
|
|
2022
Q1 | $810 | Buy |
316,520
+21,520
| +7% | +$55 | 0.18% | 81 |
|
|
2021
Q4 | $864K | Sell |
295,000
-75,000
| -20% | -$220K | 0.13% | 164 |
|
|
2021
Q3 | $907K | Buy |
370,000
+15,476
| +4% | +$37.9K | 0.21% | 86 |
|
|
2021
Q2 | $1.44M | Sell |
354,524
-70,476
| -17% | -$287K | 0.2% | 93 |
|
|
2021
Q1 | $1.92M | Buy |
425,000
+75,000
| +21% | +$338K | 0.18% | 82 |
|
|
2020
Q4 | $1.72M | Sell |
350,000
-202,856
| -37% | -$998K | 0.35% | 40 |
|
|
2020
Q3 | $3.28M | Sell |
552,856
-447,144
| -45% | -$2.65M | 0.68% | 24 |
|
|
2020
Q2 | $2.66M | Buy |
1,000,000
+494,683
| +98% | +$1.32M | 0.47% | 32 |
|
|
2020
Q1 | $985K | Buy |
+505,317
| New | +$985K | 0.2% | 87 |
|